VGF expression by T lymphocytes in patients with Alzheimer’s disease

Stefan Busse; Johann Steiner; Sarah Glorius; Henrik Dobrowolny; Sabrina Greiner-Bohl; Christian Mawrin; Ursula Bommhardt; Roland Hartig; Bernhard Bogerts; Mandy Busse

doi:10.18632/oncotarget.3569

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers: Gerotarget (Focus on Aging):

VGF expression by T lymphocytes in patients with Alzheimer’s disease

Stefan Busse _, Johann Steiner, Sarah Glorius, Henrik Dobrowolny, Sabrina Greiner-Bohl, Christian Mawrin, Ursula Bommhardt, Roland Hartig, Bernhard Bogerts and Mandy Busse

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:14843-14851. https://doi.org/10.18632/oncotarget.3569

Metrics: PDF 2554 views | HTML 2419 views | ?

Abstract

Stefan Busse1,*, Johann Steiner1,2,*, Sarah Glorius1, Henrik Dobrowolny1, Sabrina Greiner-Bohl1, Christian Mawrin3, Ursula Bommhardt4, Roland Hartig4, Bernhard Bogerts1,2 and Mandy Busse5

1 Department of Psychiatry, University of Magdeburg, Magdeburg, Germany

2 Center for Behavioral Brain Sciences, University of Magdeburg, Magdeburg, Germany

3 Department of Neuropathology, University of Magdeburg, Magdeburg, Germany

4 Institute of Molecular and Clinical Immunology, University of Magdeburg, Magdeburg, Germany

5 Department of Pediatric Pulmonology, Allergology & Neonatology, Medical University of Hannover, Hannover, Germany

* These authors contributed equally to this work

Correspondence to:

Stefan Busse, email:

Keywords: Alzheimer’s disease, T cells, VGF expression, rivastigmine, rapamycin, geotarget

Received: January 06, 2015 Accepted: February 22, 2015 Published: March 14, 2015

Abstract

Secretion of VGF is increased in cerebrospinal fluid and blood in neurodegenerative disorders like Alzheimer’s disease (AD) and VGF is a potential biomarker for these disorders. We have shown that VGF is expressed in peripheral T cells and is correlated with T cell survival and cytokine secretion. The frequency of VGF+CD3+ T cells increases with normal aging. We found an increased number of VGF-expressing T cells in patients with AD compared to aged healthy controls, which was associated with enhanced HbA1c levels in blood. Upon treatment with rivastigmine, T cell proliferation and VGF expression in AD patients decreased to the level found in controls. Moreover, rapamycin treatment in vitro reduced the number of VGF+CD3+ cells in AD patients to control levels.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3569

Publication Alerts

Research Papers: Gerotarget (Focus on Aging):

VGF expression by T lymphocytes in patients with Alzheimer’s disease

Abstract